References
- Eriksson U, Alitalo K (1999). Structure expression and receptorbinding properties of novel vascular endothelial growth factors. In: Claesson-Welsb L, editor. Vascular Growth Factors and Angiogenesis. Berlin Springer-Verlag
- Fellmer PT, Sato K, Tanaka R, et al (1999). Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery, 126, 1056. https://doi.org/10.1067/msy.2099.101432
- Jeltsch M, Kaipainen A, Joukov V, et al (1997). Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science, 276, 1423-5. https://doi.org/10.1126/science.276.5317.1423
- Joukov V, Pajusola K, Kaipainen A, et al (1996). A new vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J, 15, 290.
- Kaipainen A, Korhonen J, Mustonen T, et al (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA, 92, 3566-70. https://doi.org/10.1073/pnas.92.8.3566
- Kowalski LP, Medina JE (1998). Nodal metastases: predictive factors. Otolaryngol Clin North Am, 31, 621-37. https://doi.org/10.1016/S0030-6665(05)70076-1
- Kukk E, Lymboussaki A, Taira S, et al (1996). VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development, 122, 3829-37.
- Mork J (1998). Forty years of monitoring head and neck cancer in Norway--no good news. Anticancer Res, 18, 3705-8.
- Ogawa S, Oku A, Sawano A, et al (1998). A novel type of vascular endothelial factor, VEGF-E (NA-7 VEGF), preferentially utilizes KDR/Flt-1 receptor and carries apotent mitotic activity without beparin-binding domain. J Biol Chem, 273, 31273. https://doi.org/10.1074/jbc.273.47.31273
- Oh SJ, Jeltsch MM, Birkenhager R, et al (1997). VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol, 188, 96-109. https://doi.org/10.1006/dbio.1997.8639
- Pajusola K, Aprelikova O, Korhonen J, et al (1992). FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res, 52, 5738-43.
- Salven P, Lymboussaki A, Heikkila P, et al (1998). Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human cancers. Am J Pathol, 153, 103- 8. https://doi.org/10.1016/S0002-9440(10)65550-2
- Shushanov S, Bronstein M, Adelaide J (2000). VEGFc and VEGFR3 expression in human thyroid pathologies. Int j cancer, 86, 47. https://doi.org/10.1002/(SICI)1097-0215(20000401)86:1<47::AID-IJC7>3.0.CO;2-R
- Sobin LH, Wittekind Ch (1997). UICC TNM classification of malignant cancers, 5thed. New York John Wiley.
- Tsurusaki T, Kanda S, Sakai H, et al (1999). Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer, 80, 309. https://doi.org/10.1038/sj.bjc.6690356
- Veikkola T, Alitalo K (1999). VEGFs receptors and angiogenesis. Scmin Cancer Biol, 9, 211. https://doi.org/10.1006/scbi.1998.0091
- Yamamoto E, Kohama G, Sunakawa H, et al (1983). Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer, 51, 2175-80. https://doi.org/10.1002/1097-0142(19830615)51:12<2175::AID-CNCR2820511205>3.0.CO;2-M
- Yang Y, Ge RM (2002). Expression of VEGF and VEGF-C in laryngeal carcinoma and their clinical significance. J Clin Otorhinolaryngol, 16, 650.
- Yonemura Y, Fushida S, Bando E, et al (2001). Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer, 37, 918. https://doi.org/10.1016/S0959-8049(01)00015-6
- Zhongliang W, Yao C, Rueixiang L (2002). Advanced in the researches for vascular endothelial growth factor (VEGF)-C and vascular endothelial growth factor receptor (VEGFR)-3. China J Cancer Prev Treat, 9, 454.
Cited by
- Utility of VEGF and sVEGFR-1 in Bronchoalveolar Lavage Fluid for Differential Diagnosis of Primary Lung Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2443
- Endostar Combined with Cisplatin Inhibits Tumor Growth and Lymphatic Metastasis of Lewis Lung Carcinoma Xenografts in Mice vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.3079
- Relationships Between Clinical Behavior of Laryngeal Squamous Cell Carcinomas and Expression of VEGF, MMP-9 and E-Cadherin vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5301
- Prognostische Bedeutung der VEGF- und FLT-1-Expression bei Patienten mit lokal fortgeschrittenem Plattenepithelkarzinom der Kopf-Hals-Region vol.189, pp.8, 2013, https://doi.org/10.1007/s00066-013-0341-2
- CD44v3 and VEGF-C Expression and its Relationship with Lymph Node Metastasis in Squamous Cell Carcinomas of the Uterine Cervix vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.5049
- Comprehensive Analysis of Vascular Endothelial Growth Factor-C Related Factors in Stomach Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.1925
- Inflammatory vocal fold lesions associated with angiogenesis inhibition pp.10433074, 2014, https://doi.org/10.1002/hed.23550
- Diagnostic and Therapeutic Implications of the Vascular Endothelial Growth Factor Family in Cancer vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1677
- CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-4180-5